• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Matt Farber Discusses Pharmacist Role in Managing Cancer Care Costs

Video

New technologies are enabling pharmacists to play a bigger role in managing overall care delivery and the cost of care for patients with cancer, explained Matt Farber, MA, senior director of Patient Care and Advocacy for Walgreens.

New technologies are enabling pharmacists to play a bigger role in managing overall care delivery and the cost of care for patients with cancer, explained Matt Farber, MA, senior director of Patient Care and Advocacy for Walgreens.

Transcript

How can pharmacists play a role in helping reduce healthcare costs for patients with cancer?

Pharmacists can definitely play an active role in helping the overall care delivery team and payers in not only managing quality cancer care but also looking at overall costs. So I think first and foremost is to make sure that they are working actively with the care team, communicating with them actively at all points in care, again there's some new technologies there that can be helpful. We have more and more tools that patients are using.

For example, you know, cloud-based health records and apps that allow patients to take their drug lists with them so when a pharmacist asks about potential drug interactions they don't rely on the patient to say, "Oh, I'm taking XYZ." They can now scan a QR code that will allow them to see what medications a patient has been on or what's on their medical record, and by doing so it's sharing it in compliant ways. And so I think that, by doing that, by being more proactive around things like medication therapy management, drug interactions, those types of things that are commonplace for the pharmacists to do that they do every day.

You know, when you start to put it together with everything else it really can start to impact the overall care of the patient. So if we can do that we can hopefully keep them on their therapy longer, healthier hopefully, which again in the long run will probably reduce overall costs if we're able to keep them out of hospital emergency rooms, or from getting unnecessary procedures, or taking drugs that we know would negatively interact with other medications they may be on.

Related Videos
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
dr krystyn van vliet
Martin Dahl, PhD, senior vice president, AnaptysBio
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences
Monica Li, MD, University of British Columbia
Robert Sidbury, MD, MPH, FAAD, professor of pediatrics, division head of dermatology, Seattle Children's Hospital, University of Washington School of Medicine
Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.